Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887196 | 1.00 | TERT (0.52) | TERTGSRFOLH1NOD1SLC6A5 | |
| SCHEMBL29915442 | 0.97 | TERT (0.50) | TERTGSRFOLH1NOD1SLC6A5 | |
| SCHEMBL21190713 | 0.95 | NOD1 (0.50) | TERTGSRFOLH1NOD1SLC6A5 | |
| SCHEMBL29670883 | 0.92 | FOLH1 (0.59) | TERTGSRFOLH1NOD1SLC6A5 | |
| SCHEMBL29569049 | 0.92 | FOLH1 (0.46) | TERTGSRFOLH1NOD1SLC6A5 | |
| SCHEMBL30697803 | 0.92 | FOLH1 (0.59) | TERTGSRFOLH1NOD1SLC6A5 | |
| SCHEMBL31188441 | 0.92 | TERT (0.53) | TERTGSRFOLH1NOD1SLC6A5 | |
| SCHEMBL30828464 | 0.92 | FOLH1 (0.48) | TERTGSRFOLH1NOD1SLC6A5 | |
| SCHEMBL30254935 | 0.91 | FOLH1 (0.48) | TERTGSRFOLH1NOD1SLC6A5 | |
| SCHEMBL30785838 | 0.91 | FOLH1 (0.48) | TERTGSRFOLH1NOD1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482853-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2025-01-01 | — | — | EP | claimed |
| CN-118891273-A | Annexin A1 derived polypeptide analogs | 雷索特制药股份有限公司 | 2024-11-01 | — | — | CN | claimed |
| US-20230303640-A1 | EXENDIN-4 PEPTIDE ANALOGS | TXP PHARMA AG (CH) | 2023-09-28 | — | — | US | claimed |
| US-20230295255-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA APS (DK) | 2023-09-21 | — | — | US | claimed |
| WO-2023161323-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2023-08-31 | — | — | WO | claimed |
| CN-116390938-A | Exendin-4 analogues | TXP制药股份有限公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4200320-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2023-06-28 | — | — | EP | claimed |
| EP-4196495-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP Pharma GmbH (CH) | 2023-06-21 | — | — | EP | claimed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| WO-2022034062-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP PHARMA AG (CH) | 2022-02-17 | — | — | WO | claimed |
| CN-120665144-B | N-terminal fatty acid modified antibacterial peptide analogue and application thereof | 甘肃农业大学 | 2026-03-31 | — | — | CN | disclosed |
| US-20250388632-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA AS (DK) | 2025-12-25 | — | — | US | disclosed |
| US-20250319024-A1 | TARGETED NANOPARTICLES AND THEIR USES RELATED TO INFECTIOUS DISEASE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| CN-120665144-A | N-terminal fatty acid modified antibacterial peptide analogue and application thereof | 甘肃农业大学 | 2025-09-19 | — | — | CN | disclosed |
| US-20250263437-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20220331349-A1 | TARGETED NANOPARTICLES AND THEIR USES RELATED TO FUNGAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220325072-A1 | ZWITTERIONIC CROSSLINKERS, HYDROGELS COMPRISING ZWITTERIONIC CROSSLINKERS, AND METHODS FOR MAKING AND USING | UNIVERSITY OF IDAHO | 2022-10-13 | — | — | US | disclosed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | disclosed |
| WO-2022034062-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP PHARMA AG (CH) | 2022-02-17 | — | — | WO | disclosed |
| US-20100273734-A1 | Derivatives of Hyaluronic Acids | NOVOZYMES BIOPOLYMER A/S (DK) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388632-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | ANXA11, ANXA1, ANXA4 | TERT 4830/4885GSR 2076/4885FOLH1 1593/4885 |
| US-20250319024-A1 | TARGETED NANOPARTICLES AND THEIR USES RELATED TO INFECTIOUS DISEASE | CLEC4M, LGALS1, LGALS3BP | TERT 4218/4885GSR 2417/4885FOLH1 2403/4885 |
| US-20220325072-A1 | ZWITTERIONIC CROSSLINKERS, HYDROGELS COMPRISING ZWITTERIONIC CROSSLINKERS, AND METHODS FOR MAKING AND USING | ASS1, GFER, ASIC1 | TERT 3049/4885GSR 1926/4885FOLH1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.